HAL-1/20

General Information


DRACP ID  DRACP02018

Peptide Name   HAL-1/20

Sequence  GKWSKILGKLIR

Sequence Length  12

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=22±3 µM MTT assay 48 h 1
SW480 Colon adenocarcinoma Carcinoma IC50> 40 µM MTT assay 48 h 1
CCRF-CEM Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50> 40 µM MTT assay 48 h 1

Hemolytic Activity  Rat erythrocytes: IC50>200 μM

Normal (non-cancerous) Cytotoxicity  HUVEC: IC50> 100 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02018

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C66H115N19O14

Absent amino acids  ACDEFHMNPQTVY

Common amino acids  K

Mass  159515

Pl  11.92

Basic residues  4

Acidic residues  0

Hydrophobic residues  5

Net charge  4

Boman Index  -1108

Hydrophobicity  -17.5

Aliphatic Index  130

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  500

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22100226

Title  Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells

Doi 10.1016/j.peptides.2011.11.002

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.